Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.Financial_Report.xls
10-Q - QUARTERLY REPORT - ASSEMBLY BIOSCIENCES, INC.v326006_10q.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R22.htm
EX-31.1 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex31-1.htm
EX-32.1 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex32-1.htm
EX-31.2 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex31-2.htm
EX-32.2 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex32-2.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R5.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R19.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R20.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R23.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R21.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R10.htm
v2.4.0.6
Stockholders' Transactions (Tables)
9 Months Ended
Sep. 30, 2012
Stockholders' Transactions [Abstract]  
Warrant Activity and Related Information

A summary of the Company’s warrant activity and related information is as follows:

 

  Nine Months  Ended
September 30, 2012
 
       
     Weighted Average 
  Shares  Exercise Price 
Outstanding at beginning of period  956,443  $7.61 
Granted  -  $- 
Exercised  81,792  $7.00 
Outstanding at end of period  874,651  $7.67 
Warrants exercisable at end of period  874,651  $7.67
Option Activity and Related Information

A summary of the Company’s option activity and related information is as follows:

 

  Nine Months Ended
September 30, 2012
    
  Shares  Weighted
Average
Exercise
Price
  Aggregate
Intrinsic Value
 
Outstanding at beginning of period  2,046,455  $6.40  $- 
Granted  380,740  $8.46  $- 
Exercised  168,240  $6.11  $- 
             
Outstanding at end of period  2,258,955  $6.80  $- 
Options exercisable at end of period  1,850,996        
Assumptions for Weighted Average Fair Value of Options Granted

The fair value of the options granted for the nine-month period ended September 30, 2012, was based on the following assumptions:

 

    2012  
Risk-free interest rate     1.03% - 1.44 %
Expected volatility     76.31% -77.18 %
-Expected life of options     5.50 years  
Expected dividend yield     0 %
Estimated Future Stock Based Expenses Relating to Unvested Stock Options

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

 

Calendar Years Ending December 31,   Future Stock
Option
Compensation
Expense
 
2012 (October through December)   $ 693,373  
2013     1,382,334  
2014     566,351  
2015     9,914  
Total estimated future stock-based compensation expense – stock options   $ 2,651,972